Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,390 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.1% of DE Burlo Group Inc.’s holdings, making the stock its 26th largest position. DE Burlo Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,820,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares in the last quarter. Swedbank AB acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $129,257,000. Epoch Investment Partners Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after acquiring an additional 96,266 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on REGN shares. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:REGN opened at $743.35 on Thursday. The company has a 50 day moving average price of $961.76 and a two-hundred day moving average price of $1,030.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $736.01 and a 52 week high of $1,211.20. The company has a market capitalization of $81.69 billion, a PE ratio of 18.40, a PEG ratio of 2.81 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.